Pharmaceuticals, Biotechnology and Life Sciences
Premaitha has signed four-year Master Procurement Agreement (the “MPA”) with a European diagnostics services group to install the IONA test in at least two of the Groups’s laboratories.
Premaitha Health has gotten UK’s Department of Health approval to make non-invasive prenatal tests (“NIPT”)
Premaitha signs distribution agreement with GeNext in Russia
Premaitha Health, the developer of IONA test, has partnered with Leeds Teaching Hospitals NHS Trust to provide a private NIPT…
Premaitha Health said Wednesday that Adgenix has already signed up its first laboratory customer for Premaitha in France, with a signed contract for a minimum of three years to supply LaboSud with the Iona test.
Study demonstrates the IONA test can accurately predict the presence of the trisomies 21, 18, and 13. Being user-friendly, cost effective and CE-marked will overcome some of the limitations of existing commercial technologies to facilitate implementation in local laboratories.
Premaitha Health PLC, developer of the IONA test, the first CE-marked non-invasive prenatal screening test (NIPT) confirms that Chief Medical Officer, Dr William Denman, will join the Board of Premaitha as an Executive Director on 1 November 2015.
Premaitha Health plc, developer of the IONA test, the first CE-marked non-invasive prenatal screening test (NIPT) has expanded its in-house NIPT screening service by opening a dedicated laboratory which triples clinical capacity in response to demand for the IONA test from clinicians.
Premaitha Health plc, developer of the IONA test, the first CE-marked non-invasive prenatal screening test (NIPT), has announced the results of a study on the first-trimester detection of trisomy 21, 18 and 13 using the IONA test.
Premaitha Health has signed a distribution agreement with Antisel SA, a Greek distributor of scientific products, to provide the IONA test to clinical laboratories in the region.